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The so-called 'triple-negative breast cancer' (TNBC), defined as ER-/PgR-/HER2-, is a specific subtype of breast cancer accounting for 12%-20% of all breast cancer cases [1, 2] . TNBC appears to have an aggressive behavior with early visceral metastasis and consequently poorer outcomes [2, 3] . Numerous efforts are currently being undertaken to improve prognosis for patients with TNBC. It comprises both optimization in choice and scheduling of common cytotoxic agents or dose intensification strategies and introduction of novel target agents including anti-EGFR, antiangiogenesis, etc. Unfortunately, none of the target therapies has been proved to be beneficial, and some such as PARP inhibitors [4] have even turned out to be disappointing. Therefore, for the time being, chemotherapy remains to be the only possible therapeutic option in the adjuvant or metastatic setting in TNBC.
The histological similarity between BRCA1-related breast cancer and TNBC has shed some light on the choice of chemotherapy. The deficiency of BRCA1, which leads to defective DNA homologous recombination of double-strand break repair, confers hypersensitivity to the interstrand crosslinking agents such as platinum and mitomycin C [5, 6] . A few retrospective study or small-sample neoadjuvant trials have suggested that TNBC may be more sensitive to DNAdamaging agents such as CDDP [7, 8] , but others have shown contrary results [9] . The use of platinum and alkylating agents in these patients is currently under investigation by many researchers [10, 11] . Several phase II or III clinical trials testing platinum drugs in metastatic TNBC (mTNBC) patients are ongoing [12, 13] . However, to our knowledge, no published data are yet available on this particular issue. This article presents the results of the very first prospective, randomized phase II clinical trial comparing different regimens in mTNBC. 
patients and methods

study design
patients characteristics
Totally 53 patients were randomized and evaluated. Patient demographics at baseline are summarized in Table 1 . All the patients had received anthracyclines while 66.7% of patients in the TP arm and 57.7% of patients in the TX arm received paclitaxel in the adjuvant/neoadjuvant setting. The median ages were 48 (32-67) and 49 (27-71) years, respectively. Sixteen of 27 patients in the TP arm and 19 of 26 patients in the TX arm had visceral metastases. More liver metastases were detected in the TX arm, but no difference in visceral/ nonvisceral metastases was found between the two arms. Overall, the two arms were well balanced with regard to the baseline characteristics except grade 3 tumors, which was more dominant in the TP arm than in the TX arm P = 0.014).
response and survival
The ORR was 63.0% (3 CR, 14 PR) in the TP arm and 15.4% (4 PR) in the TX arm (P = 0.001). The clinical benefit rate was numerically but not statistically higher in the TP arm than in the TX arm (81.5% versus 61.5%, P = 0.135) ( Table 2 , a). Responses according to disease sites in evaluable patients are reported in detail in Table 2 , b. The response rates were unanimously higher in the TP arm than in the TX arm, no matter where the metastases were. For the secondary end points, median PFS ( Figure 2 ) was 10.9 months in the TP arm (95% CI 2.2-19.8 months) and 4.8 months in the TX arm (95% CI 3.0-6.7 months) [HR 0.29, 95% CI 0.14-0.57), P < 0.001]. Median OS was also statistically longer in the test arm than in the control arm [32.8 months versus 21.5 months, HR 0.41 (0.18-0.92), P = 0.027] as illustrated in Figure 3. safety Supplementary Table 3 , available at Annals of Oncology online, summarizes major treatment-related toxic effects. Overall, both treatment regimens were well tolerated and quite manageable. There were no treatment-related deaths. The incidence of G1/2 leukopenia and that of neutropenia were statistically higher in the TP arm than in the TX arm but no difference in other G1/2 hematological toxic effects was found. G3/4 neutropenia was similar between both arms. No G3/4 thrombocytopenia and anemia were observed. As what had been expected, GI tract toxic effects, such as vomiting (74.1% versus 34.6%, P = 0.004), were more common in the TP arm than those in the TX arm while no big differences were seen in other toxic effects, including diarrhea, fatigue, hepatic abnormalities, and neuropathy. Likewise, more instances of G2/3 hand-foot syndrome were reported in the capecitabine arm (P = 0.023).
A total of 256 cycles were given with a median of 5 cycles (range 2-6) in the TP arm and 4.6 cycles (range 2-8 cycles) in the TX arm. The dose of doctaxel was decreased in 6 patients in the TX arm because of Grade II hyperbilirunbinemia, G4 neutropenia or infection. The dose of capecitabine was modified in six patients mostly for G2/3 hand-foot syndrome and interrupted in three patients from G4 neutropenia or fever. discussion Several preclinical studies in TNBC cell lines had provided data establishing that they were more sensitive to DNA-damaging agents [6, 15] , highlighting the potential value of platinum in this phenotype. A possible explanation would be the substantial overlap between TNBC and BRCA1-related breast cancer. Although there is doubt that sporadic TNBC are not carriers of BRCA1 mutation, there is evidence of BRCA1 pathway dysfunction in these tumors such as by epigenetic mechanisms [16] . Recently, a molecular pathway by which cisplatin induces cell death selectively in TNBC has been discovered, which suggests that p53 family members p63/p73 may play an important role in mediating platinum sensitivity in TNBC [17] . This hypothesis seems to be supported in neoadjuvant treatment of TNBC patients. Garber first reported in 2006 SABCS meeting that cisplatin monotherapy can achieve an ORR of 50% and a 22% pCR in TNBC patients. Decreased BRCA1 expression may identify subsets of TNBCs that are CDDP sensitive [8] . This was followed by Byrski et al. [18] , showing that in a neoadjuvant setting a rather high rate of pathological CR was observed after treatment with CDDP in 10 (83%) of 12 BRCA1 mutation carriers. Platinum agents have also been proved to be effective in combination with other agents, including paclitaxel and bevacizumab in the neoadjuvant setting [19, 20] .
However, it was not the same in all cases in a metastatic setting. The study by Sirohi et al. [7] retrospectively reviewed 155 patients treated by platinum-based chemotherapy (PBCT) for MBC and then analyzed outcomes according to the TNBC status. There was a slight significant gain in median PFS for TNBC patients (6 versus 4 months, P = 0.05), a nonsignificant trend toward improvement of ORR (41% for TNBC versus 31% for non-TNBC, P = 0.3) and similar OS. The authors concluded that PBCT could slightly improve the poor prognosis of TNBC. Nevertheless, in a recent report of Staudacher [9] , among143 patients treated for metastatic breast cancer with PBCT, although ORR was higher (33.3% versus 22%, P = 0.1) in the TNBC group than the non-TNBC group, no difference in OS or PFS was observed.
So the question that remains to be asked is: are platinum specific to TNBC? Docetaxel and capecitabine is one of the most common choices in first-line treatment of MBC. However, in the present study of mTNBC patients, cisplatinbased combination chemotherapy demonstrated not only higher response rate but also remarkable improvement in PFS and OS compared with the TX regimen, even though 12 of 26 patients from the TX group received platinum-based chemotherapy in the second-line treatment. Although it is not suitable to draw a conclusion on survival advantage from merely a phase II trial, it is without doubt that in this subtype, it is cisplatin that generated extra clinical benefit out of these agents. The absolute values of PFS and OS in this group of TNBC patients were almost equal to what we have seen in so-called 'better'Luminal type or HER2 positive MBC after treatment of trastuzumab-based regimen. To further elaborate on this question, let u's look back at the literature on the efficacy of cisplatin in MBC. The response rate of cisplatin was reported to be 42%-54% as single agent [21, 22] . If combined with docetaxel, the response rate was in the range 40%-70% and PFS/TTP was in the range 5-11 months [23] [24] [25] . It seems that these results in general MBC patients were similar to what we have seen in mTNBC patients of our study. But the fact was that quite a few patients in the literature were anthracyclinesnaive. Furthermore, none of them received paclitaxel previously while all the TNBC patients in our trial were anthracyclines-pretreated and two-thirds were paclitaxel treated. As we all know, when given after other chemotherapy, the response rate of cisplatin fell to 0%-9% [26, 27] . So one can speculate that it is possible that TNBC is more sensitive to cisplatin than non-TNBC. Although this study canno't yet tell for sure whether cisplatin is more efficacious in TNBC than non-TNBC, cisplatin is without doubt very effective in mTNBC.
The role of capecitabine in TNBC is even more insufficiently discussed, no work addressing this particular issue is found in the literature. Clues can be found only from retrospective subgroup analyses. In the famous FinXX study comparing recurrence-free survival with XT → CEX versus T → CEF as adjuvant therapy in patients with earlystage BC, XT → CEX improved RFS only in women with triple-negative disease (HR, 0.48; P = 0.0177) [28] . A similar trend was also observed in another capecitabine adjuvant study USON01062 trial [29] . However, studies in MBC indicated that capecitabine may not be suggested in mTNBC. In the randomized phase III trial comparing capecitabine-ixabepilone with capecitabine monotherapy, 1712 patients were treated with prior anthracycline and taxanes therapy, and 857 patients received capecitabine alone, of which 208 patients were TNBC patients. The overall response rate and PFS in the capecitabine monotherapy arm were 25% and 4.2 months in the overall population, but only 15% and 1.7 months in the TNBC subgroup [30] , respectively. Furthermore, a single-arm phase II study of capecitabine with bevacizumab found that the response rate was nearly double in ER+ patients compared with triple-negative patients (47% versus 27%) with a similar difference in time to progression (8.9 versus 4.0 months) and OS (>16.6 versus 7.5 months) [31] .
However, based on Kotsori's study, among 89 mTNBC patients receiving capecitabine monotherapy as first to third line treatment, the response rate was 21% and OS was 39 weeks. The investigator concluded that capecitabine was a feasible treatment choice in mTNBC [32] . But as a matter of fact, the median TTP was only 11 weeks even in first-line treatment, which was definitely far from satisfaction. Even combined with docetaxel, as in our study, the PFS was just 4.8 months, which was not much better than results mentioned above. So capecitabine seems to have limited potency in mTNBC. Of course, it i's too early to say that capecitabine should be avoided, since all these results came from retrospective analyses or small-sample studies. After all, capecitabine is one of the mainstay chemotherapeutic agents after anthracyclines and taxanes failure. Besides, one of the shortcomings of this study was that capecitabine was stopped after 6 cycles of combination therapy and it is possible that capecitabine can play a role in maintenance treatment. Since these two regimens had been previously well studied and reported, toxic effects were not the main focus of this study. It turned out that the toxicity profile in our study was just as expected: Gastrointestinal toxic effects were more common in the cisplatin group, while hand-foot syndrome was mostly in the capecitabine group. Both regimens were well manageable.
Of course, there are some limitations of this open-label, phase II study, including small sample size and potential investigator bias as a single-institution study and inconsistence of the hormone receptor positivity cutoff due to the modification of international guidelines during the trial. Another issue is that TNBC is heterogeneous and response to chemotherapy might be different between basal and nonbasal TNBC. There possibly were imbalances of TNBC subtypes on the study arms. Despite its limitations, this phase II study provides proof of concept that cisplatin is considerably effective in TNBC and if not contraindicated, cisplatin, rather than capecitabine, might be a better first-line treatment choice. Capecitabine is acceptable but may play a limited role in mTNBC patients. The results are not sufficient to change clinical practice and need to be further validated in a large cohort of patients.
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